UroGen Pharma GAAP EPS of -$0.28 in-line, revenue of $72.5M beats by $8.96M; updates FY
· seekingalpha.com
UroGen Pharma press release (URGN): Q2 GAAP EPS of -$0.28 in-line. Revenue of $72.5M (+199.6% Y/Y) beats by $8.96M.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...